statistiche ricercatore

Continente	#
NA - Nord America	346
AS - Asia	314
EU - Europa	215
SA - Sud America	41
Continente sconosciuto - Info sul continente non disponibili	37
AF - Africa	10
Totale	963

Nazione	#
US - Stati Uniti d'America	328
SG - Singapore	120
IT - Italia	93
VN - Vietnam	63
HK - Hong Kong	44
CN - Cina	36
BR - Brasile	31
IE - Irlanda	29
RU - Federazione Russa	22
DE - Germania	21
CA - Canada	12
FI - Finlandia	10
KR - Corea	10
GB - Regno Unito	8
AR - Argentina	5
BD - Bangladesh	5
FR - Francia	5
IN - India	5
LT - Lituania	5
PH - Filippine	5
SE - Svezia	5
ET - Etiopia	4
JP - Giappone	4
NL - Olanda	4
TH - Thailandia	4
AT - Austria	3
GT - Guatemala	3
TR - Turchia	3
AZ - Azerbaigian	2
CO - Colombia	2
EG - Egitto	2
ES - Italia	2
IQ - Iraq	2
PL - Polonia	2
SA - Arabia Saudita	2
SC - Seychelles	2
UA - Ucraina	2
ZA - Sudafrica	2
BE - Belgio	1
BO - Bolivia	1
BS - Bahamas	1
CH - Svizzera	1
CW - ???statistics.table.value.countryCode.CW???	1
EC - Ecuador	1
EU - Europa	1
HN - Honduras	1
HR - Croazia	1
ID - Indonesia	1
JO - Giordania	1
KW - Kuwait	1
LB - Libano	1
MX - Messico	1
MY - Malesia	1
OM - Oman	1
PE - Perù	1
PK - Pakistan	1
PT - Portogallo	1
QA - Qatar	1
UZ - Uzbekistan	1
Totale	928

Nome	#
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice	185
ARPIR: automatic RNA-Seq pipelines with interactive report	148
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations	134
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML	117
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML	115
IL3-zetakine combined with a CD33 costimulatory receptor as a Dual CAR approach for safer and selective targeting of AML	115
SiCoDEA: A Simple, Fast and Complete App for Analyzing the Effect of Individual Drugs and Their Combinations	85
Omacetaxine mepessucinate plus venetoclax show strong synergistic anti-leukemic activity in nucleophosmin (NPM1)-mutated AML patient-derived xenograft (PDX) models to support a phase 1 clinical trial	36
ISOCITRATE DEHYDROGENASES AML-ASSOCIATED POINT MUTATIONS DRIVE A BLOCK OF DIFFERENTIATION IN HUMAN NORMAL CD34+HEMATOPOIETIC CELLS THAT IS RELEASED BY SPECIFIC INHIBITORS	28
Totale	963

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	38	0	0	0	0	2	0	0	9	1	7	8	11
2022/2023	103	4	20	1	9	5	10	3	2	33	8	6	2
2023/2024	73	2	6	5	4	0	2	17	2	5	7	9	14
2024/2025	195	7	13	4	10	16	15	30	31	30	7	19	13
2025/2026	385	18	24	13	39	45	38	54	22	70	46	9	7
2026/2027	75	15	16	25	19	0	0	0	0	0	0	0	0
Totale													963

IRIS - Res&Arch Institutional Research Information System - Research & Archive